GlaxoSmithKline (GSK) has announced it will invest $30 billion in the United States over the next five years, focussing on research, development, and enhancing its supply chain infrastructure.
The move comes as U.S. President Donald Trump begins a state visit to the United Kingdom.
A key part of the plan is a $1.2 billion biologics manufacturing facility in Upper Merion, Pennsylvania, set to produce treatments for cancer and respiratory illnesses starting in 2026.
GSK will also expand AI and digital tech infrastructure at its U.S. manufacturing sites, grow drug substance production, and enhance device and auto-injector assembly lines.
The investment is seen in the context of threatened pharmaceutical tariffs under the Trump administration, prompting drugmakers to build more U.S. manufacturing capacity and reduce reliance on imports.
GSK said the development will generate tens of thousands of jobs in the U.S. and reinforce U.K.-U.S. life sciences collaboration.
